Back to Market返回行情

AXGN AxoGen, Inc.

USHealthcare
$40.58-6.97%ClosedMarket Cap: $2.16B

As of 2026-07-10 16:00

Why AXGN matters now

AxoGen, Inc. (AXGN) is a US stock in Healthcare. The latest InvestLog snapshot shows $40.58 with -6.97% on the session and $2.16B in market capitalization; recent performance reads 1-month +5.04% and YTD +37.00%.

The latest financial table shown here is Q1 2026, with revenue of $61.5M, net income of $-19.6M, and EPS of $-0.38. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 0.4%.

The latest indexable market news headline is "AxoGen, Stock Of The Day, Offers Entry After Bullish Rebound" from Investors Business Daily.

Additional event context on this page matters because analyst consensus is Buy with a median target of $49.00; recent insider activity includes Wendell Amy McBride filing M-Exempt. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

9.45

P/S

10.01

EV/EBITDA

-281.89

DCF Value

$-24.69

FCF Yield

0.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

75.0%

Operating Margin

-3.8%

Net Margin

-13.2%

ROE

-20.7%

ROA

-10.9%

ROIC

-3.4%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$61.5M$-19.6M$-0.38
Q4 2025$59.9M$-13.2M$-0.28
FY 2025$225.2M$-15.7M$-0.34
Q3 2025$60.1M$708.0K$0.01

Analyst Ratings

Consensus

Buy

Target (Consensus)

$47.00

Target (Median)

$49.00

Target Range

$40.00 - $50.00

Strong Buy: 2Buy: 7Hold: 0Sell: 0Strong Sell: 0
CitizensMarket Outperform
2026-04-29
HC Wainwright & Co.Buy
2026-04-29
Wells FargoOverweight
2026-04-29
Canaccord GenuityBuy
2026-04-29
Lake StreetBuy
2026-04-23

Trading Activity

Insider Trades

Wendell Amy McBridedirector
Sell2026-05-12
Wendell Amy McBridedirector
Sell2026-05-12
Wendell Amy McBridedirector
Sell2026-05-12
Quackenbush Dorisofficer: Sales VP
Sell2026-05-08
Hartley Lindsey Marieofficer: CFO
Sell2026-05-08

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

Beta

1.12

AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.